Shots: The agreement involves assessing of FLXBio’s FLX475 candidate with Merck’s Keytruda (pembrolizumab) in the ongoing P-I/II as an anti-PD-1 therapy in patients with multiple types of cancer The study will evaluate efficacy, safety & tolerability of FLX475 as a monothx and in combination with Keytruda in various centers including the US, Australia and Asia FLX475 […]Read More
